Equities

Moberg Pharma AB (publ)

Moberg Pharma AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)18.26
  • Today's Change-0.93 / -4.85%
  • Shares traded321.62k
  • 1 Year change+93.23%
  • Beta0.7699
Data delayed at least 15 minutes, as of Nov 22 2024 16:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments61126103
Total Receivables, Net0.791.441.14
Total Inventory7.12----
Prepaid expenses1.040.770.29
Other current assets, total----0.57
Total current assets69128105
Property, plant & equipment, net4.945.984.52
Goodwill, net------
Intangibles, net532408327
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets635564451
LIABILITIES
Accounts payable6.77175.31
Accrued expenses9.236.546.57
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.272.122.70
Other current liabilities, total3.271.020.97
Total current liabilities212716
Total long term debt3.473.991.24
Total debt4.746.113.93
Deferred income tax------
Minority interest----0
Other liabilities, total00.070.07
Total liabilities243117
SHAREHOLDERS EQUITY
Common stock289.834.41
Additional paid-in capital921841731
Retained earnings (accumulated deficit)(339)(317)(302)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity611534434
Total liabilities & shareholders' equity635564451
Total common shares outstanding28156.84
Treasury shares - common primary issue0.450.390.23
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.